CN104161678A - Cosmetic - Google Patents
Cosmetic Download PDFInfo
- Publication number
- CN104161678A CN104161678A CN201410284294.5A CN201410284294A CN104161678A CN 104161678 A CN104161678 A CN 104161678A CN 201410284294 A CN201410284294 A CN 201410284294A CN 104161678 A CN104161678 A CN 104161678A
- Authority
- CN
- China
- Prior art keywords
- cosmetics
- formula
- polyhydroxy
- parts
- cosmetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides a cosmetic, comprising an effective amount of a compound represented by a formula I. A structure of the compound represented by the formula I is shown in the description. In the formula I, X is selected from alkali-metal elements. The cosmetic provided by the invention comprises an effective amount of 9,10,12-trihydroxy stearate derivative. The derivative has a certain anti-bacterial activity, and has an anti-bacterial effect for some bacteria close to that of antibiotics such as chloramphenicol. By using the derivative in daily-use cosmetic, the deterioration problem of the cosmetic brought by bacteria can be effectively prevented or delayed, and a shelf life of the cosmetic can be prolonged.
Description
Technical field
The present invention relates to a kind of cosmetics.
Background technology
For a long time, Dermatology expert, cosmetics expert can effectively maintain human skin striving to find, or are some dermopathic all kinds of natural materials or synthetic material for the treatment of.Now, cosmetics have developed into a relatively flourishing period, and the cosmetics of various forms, various functions, skin care item are tinkling of jades meets the eye on every side.In numerous skin care item, contain natural non-stimulated composition, really effectively the product of the formula of skin care composition is that skin care item manufacturing enterprise and skin care item consumer are pursued always.And the skin care item that can actually meet this requirement often become expensive luxury goods, can not be for becoming majority's consumer objects.
In cosmetics, adding antibiotic antiseptic, is to extend the cosmetics shelf-life, increases the effective ways of shelf life.Directly extracting by synthetic or natural product is the main path in household chemicals antiseptic, antibacterial source, but all there is certain defect in both modes, synthetic household chemicals antiseptic, antibacterial, as imidazolidinyl urea, parabens, often its manufacturing cost is higher, and in manufacture process, cause comparatively serious environmental pollution, the wasting of resources etc.The defects such as conventionally to have stability as the material of household chemicals antiseptic, antibacterial not good enough and directly extract from natural product, and water solublity is bad, and antisepsis and sterilization effect is not ideal enough.
Castor oil acid, is that the best natural plants organic acid of permeability is found in the research of skin now being made through retrofit by Oleum Ricini, is mainly used at present surfactant, plasticizer, lube oil additive etc.Yet there are no castor oil acid and derivant thereof are reported for the research of the efficient fine chemical product such as antiseptic, antibacterial aspect.
Summary of the invention
The object of the present invention is to provide the cosmetics that contain 9,10,12-trihydroxy octadecanoate analog derivative.
Particularly, the invention provides a kind of cosmetics, the formula I compound that it contains effective dose; Formula I compound structure is as follows:
X is selected from alkali metal.
Further, X is selected from K or Na.
Wherein, formula I compound accounts for 1～10% of cosmetics total amount.
Further, formula I compound accounts for 1～5% of cosmetics total amount.
Further, formula I compound accounts for 3～5% of cosmetics total amount.
Wherein, in described cosmetics, also comprise oil phase substrate, consistency modifiers, wetting agent, emulsifying agent and water.
Further, described oil phase substrate is squalane; Described consistency modifiers is glyceryl monostearate and octadecanol; Described wetting agent is Polyethylene Glycol, glycerol and propylene glycol; Described emulsifying agent is Span-80 and Tween-80.
Further, in described cosmetics, also comprise essence, auxiliary anticorrosion agent.
In cosmetics provided by the invention, contain 9 of effective dose, 10,12-trihydroxy octadecanoate analog derivative, this analog derivative has certain antibacterial activity, and the antibacterial action of some antibacterial is approached to the antibiotic activities such as chloromycetin, uses it for daily cosmetics, can effectively avoid or delay the spoilage problems that antibacterial brings cosmetics, extend commodity shelf life.
In some embodiments, one or more compounds of the present invention use that can combine with one another.Also can select compound of the present invention to be combined with any other active agent, for the preparation of medicine or the longer cosmetics of shelf-life with antibiotic effect.
Obviously,, according to foregoing of the present invention, according to ordinary skill knowledge and the means of this area, not departing under the above-mentioned basic fundamental thought of the present invention prerequisite, can also make amendment, replacement or the change of other various ways.
By the form of specific embodiment, foregoing of the present invention is described in further detail again below.But this should be interpreted as to the scope of the above-mentioned theme of the present invention only limits to following embodiment.All technology realizing based on foregoing of the present invention all belong to scope of the present invention.
Brief description of the drawings
Fig. 1 bacillus subtilis is 48h growth curve in variable concentrations polyhydroxy sodium ricinoleate
The growth curve of Fig. 2 bacillus subtilis in variable concentrations polyhydroxy potassium ricinoleate
Detailed description of the invention
Embodiment 19, the preparation of the stearic salt derivative of 10,12-trihydroxy
The alcoholic solution of the sodium hydroxide of equivalent (potassium) is added drop-wise to polyhydroxy castor oil acid in the solution of ethanol at 80 DEG C, after being added dropwise to complete, reaction mixture continues to stir 1-1.5h and is as cold as room temperature until the PH of reactant liquor is 7. reactant liquors, ethanol is removed in decompression, the faint yellow solid obtaining is sodium (potassium) salt of polyhydroxy castor oil acid, yield >98%. fusing point: 202-208 DEG C (fusing point of potassium salt and sodium salt is consistent) after drying.
1H NMR (400MHz) (DMSO-d
6) 0.85 (t, 3H), 1.23-1.38 (m, 24H), 1.85 (t, 2H), 3.17-3.59 (m, 3H), 4.6 (br, 3H) (potassium salt).
1H NMR (400MHz) (DMSO-d
6) 0.81 (t, 3H), 1.17-1.42 (m, 24H), 1.79 (t, 2H), 3.10-3.60 (m, 3H), 4.6 (br, 3H) (sodium salt).
Embodiment 2: the preparation of cosmetics
Preparation condition: water and water-soluble composition (are specially to 500 parts of Purified Waters, 60 parts of glycerol, 30 parts of propylene glycol, 30 parts of Polyethylene Glycol, 30 parts of polyhydroxy ricinates, the umber of described composition refers to weight portion) at vessel in heating to 90 DEG C sterilizing 20min, then be cooled to 80 DEG C for subsequent use; By oil phase and lipophilic component (be specially 215 parts of squalanes, 30 parts of glyceryl monostearates, 30 parts of octadecanol, span ?8050 parts, tween ?8028 parts, the umber of described composition refers to weight portion) be heated with stirring to and melt (approximately 75 DEG C) completely, by the mixing speed modulation 1000r/min in oil phase container, slowly water for subsequent use is added in the whirlpool of oil phase, complete, holding temperature and mixing speed, emulsifying 30min; System temperature is down to 45 DEG C and adds essence and antiseptic, Reasonable Speed stirs; System temperature is down to room temperature, ageing; Packaging gets product.Polyhydroxy ricinate in formula is substituted as a control group with Purified Water equivalent, result shows, the product of addition polyhydroxy ricinate finished product is placed and within six months, is not occurred above any denaturalization phenomenon, and mildew phenomena appearred in matched group in six months.
Embodiment 3: the preparation of cosmetics
Preparation condition: water and water-soluble composition (are specially to 500 parts of Purified Waters, 60 parts of glycerol, 30 parts of propylene glycol, 30 parts of Polyethylene Glycol, 30 parts of polyhydroxy ricinates, the umber of described composition refers to weight portion) at vessel in heating to 90 DEG C sterilizing 20min, then be cooled to 80 DEG C for subsequent use; By oil phase and lipophilic component (be specially 215 parts of squalanes, 30 parts of polyhydroxy castor oil acids, 30 parts of glyceryl monostearates, 30 parts of octadecanol, span ?8050 parts, tween ?8028 parts, the umber of described composition refers to weight portion) be heated to melt completely (approximately 75 DEG C), by the mixing speed modulation 1000r/min in oil phase container, slowly water for subsequent use is added in the whirlpool of oil phase, complete, holding temperature and mixing speed, emulsifying 30min; System temperature is down to 45 DEG C and adds essence and antiseptic, Reasonable Speed stirs; System temperature is down to room temperature, ageing; Packaging gets product.Polyhydroxy castor oil acid composition in formula is substituted as three matched groups using blank, Purified Water, equivalent respectively, make the comparison of cosmetics finished product.Result shows the finished product that contains polyhydroxy castor oil acid composition in formula, has more good outward appearance and skin comfort level.Polyhydroxy ricinate in formula is substituted as a control group with Purified Water equivalent, result demonstration, the product of addition polyhydroxy ricinate finished product is placed and within six months, is not occurred above any denaturalization phenomenon, and in six months, there is mildew phenomena in matched group.
Illustrate beneficial effect of the present invention by test example below.
Test example 1 antibacterial activity test
According to antibacterial activity test conventional method and polyhydroxy ricinate (potassium salt prepared by embodiment 1 or sodium salt, below can be called polyhydroxy potassium ricinoleate or polyhydroxy sodium ricinoleate) characteristic that has, select water as solvent carrier, test respectively the inhibition of polyhydroxy castor oil acid salt pair gram negative bacteria, gram positive bacteria.
(1) antibacterial activity test adopts the assay method of Oxford agar diffusion method minimal inhibitory concentration:
Configure variable concentrations gradient according to antibacterial activity method of testing: 100,50,25,12.5,6.25,3.13,1.56 (mg/ml) sample solution, and select the representative mushroom of gram negative bacteria, gram positive bacteria: bacillus subtilis, staphylococcus aureus, Pseudomonas aeruginosa, escherichia coli, carry out the antibacterial activity test experiments of system.
Wherein the test data of polyhydroxy sodium ricinoleate is as follows:
Table 1
Wherein the test data of polyhydroxy potassium ricinoleate is as follows:
Table 2
Note: in table 1,2, "+" representative has obvious antibacterial activity, and "+" is more, and activity is stronger; "-" represents that antibacterial activity is not obvious, the diameter of inhibition zone in the digitized representation sterilization experiment in form, and numerical value is larger, and bacteriostatic activity is stronger.
From table 1,2, polyhydroxy sodium ricinoleate is to bacillus subtilis, staphylococcus aureus, and Pseudomonas aeruginosa, colibacillary minimal inhibitory concentration is respectively: 1.56,3.13,6.25,50 (mg/ml); Polyhydroxy potassium ricinoleate bacillus subtilis, staphylococcus aureus, Pseudomonas aeruginosa, colibacillary minimal inhibitory concentration is respectively: 1.56,6.25,12.5,50 (mg/ml).
(2) growth curve method is measured
Impact and the minimal inhibitory concentration thereof of sample concentration on each confession examination bacteria growing state:
A, bacillus subtilis 48h growth curve in variable concentrations polyhydroxy sodium ricinoleate the results are shown in Figure 1
B, the growth curve of bacillus subtilis in variable concentrations polyhydroxy potassium ricinoleate: the results are shown in Figure 2
Result shows: can intuitively reflect impact and the minimal inhibitory concentration thereof of variable concentrations sample on thalli growth state by growth curve of bacteria, along with the increase of sample concentration, curve is tending towards straight line, thalli growth is suppressed obviously, as above figure can find out that polyhydroxy sodium ricinoleate and polyhydroxy potassium ricinoleate are 1.56mg/ml to bacillus subtilis minimal inhibitory concentration, consistent with Oxford agar diffusion method result.
(3) polyhydroxy sodium ricinoleate and polyhydroxy potassium ricinoleate are with respect to the titration of antibiotic chloromycetin
With bacillus subtilis and Pseudomonas aeruginosa for representing strain, test sample contrast chloromycetin gradient concentration antibiotic property.
Preparation chloromycetin solution concentration is 200,150,100,75,50,37.5,25,18.75,12.5,9.38,6.25,4.69 (mg/ml), and bacillus subtilis, the Pseudomonas aeruginosa of activation 24h are diluted to 10
7individual/ml.Get respectively 2ml and add to lower than in 50 DEG C of LB culture medium, every dull and stereotyped 20ml, makes the flat board that carries disease germs, equidistant placement Oxford cup, and the sample 200ul that annotates, and three parallel controls of each bacterium, repeat for three times.
Table 3
Average diameter:
Table 4
| Concentration | 200 | 150 | 100 | 75 | 50 | 37.5 | 25 | 18.75 | 12.5 | 9.38 | 6.25 | 4.69 |
| Concentration logarithm | 2.30 | 2.18 | 2 | 1.88 | 1.70 | 1.57 | 1.40 | 1.27 | 1.1 | 0.97 | 0.8 | 0.67 |
| Hay brood cell bar | 1.31 | 1.23 | 1.15 | 1.07 | 0.99 | 0.93 | 0.86 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 |
| The false unit cell of Aerugo | 2.0 | 1.86 | 1.66 | 1.46 | 1.26 | 1.15 | 0.98 | 0.91 | 0.88 | 0.86 | 0.83 | 0.8 |
Chloramphenicol concentration logarithm value and Bacillus subtillis antibacterial circle diameter standard curve: regression equation: y=0.4907x+1.656, R
2=0.9964
Chloramphenicol concentration logarithm value and Pseudomonas aeruginosa antibacterial circle diameter standard curve: regression equation: y=1.1569x-0.6710, R
2=0.9949
If get polyhydroxy sodium ricinoleate and the polyhydroxy potassium ricinoleate antibacterial circle diameter to bacillus subtilis and Pseudomonas aeruginosa of concentration while being 100mg/ml, can calculate it and be equivalent to tiring of antibiotic chloromycetin and be respectively:
Table 5
Result shows: the tiring of water-soluble sample polyhydroxy sodium ricinoleate salt pair bacillus subtilis when concentration is 100mg/ml and Pseudomonas aeruginosa, be equivalent to respectively chloromycetin 5.02,111.94 (mg/ml), sample polyhydroxy potassium ricinoleate tiring to bacillus subtilis and Pseudomonas aeruginosa, be equivalent to respectively chloromycetin 1.69,61.66 (mg/ml)
Conclusion: comprehensive above-mentioned test is known, salt derivative prepared by the present invention possesses certain antibacterial activity, wherein, polyhydroxy sodium ricinoleate is to bacillus subtilis, staphylococcus aureus, Pseudomonas aeruginosa, colibacillary minimal inhibitory concentration is respectively: 1.56,3.13,6.25,50 (mg/ml); Polyhydroxy potassium ricinoleate is to bacillus subtilis, staphylococcus aureus, Pseudomonas aeruginosa, colibacillary minimal inhibitory concentration is respectively: 1.56,6.25,12.5,50 (mg/ml), and, the antibacterial activity of some antibacterial is approached to chloromycetin.
The impact of test example 2 derivant of the present invention on article of everyday use
The skin care item formula that design contains polyhydroxy ricinate, calculate the using dosage of polyhydroxy ricinate according to formulation Design Principle, exemplify formula as follows: 200 parts of squalanes, 400 parts of white oils, 100 parts of stearyl alcohols, 50 parts of glyceryl monostearates, 900 parts of deionized waters, 200 parts of glycerol, 200 parts of Polyethylene Glycol (200 is poly-), 40 parts of polyhydroxy ricinates, in above-mentioned data, umber refers to weight portion.
Prepare the cold cream frost finished product that contains polyhydroxy ricinate: 1, the deionized water in formula, glycerol, Polyethylene Glycol, polyhydroxy ricinate are mixed, be heated with stirring to 80 DEG C for subsequent use; 2, squalane, white oil, stearyl alcohol, glyceryl monostearate etc. are heated with stirring to and are molten into transparent oily liquid completely, approximately 72 DEG C; 3, the water in 1 step is slowly added in the whirlpool of 2 step oil phases, water adds complete, and mixing speed is modulated to 1000r/min, emulsifying 20min; 4, system temperature is down to 45 DEG C, adds appropriate essence and skin-care effect composition; 5, continue system temperature to be down to room temperature, bottle, by the time contain the cold cream frost finished product of polyhydroxy castor oil acid salt component.The cold cream frost finished product that does not simultaneously add polyhydroxy ricinate with identical composition and engineering condition preparation in contrast.
The cold cream that contains polyhydroxy castor oil acid salt component frost finished product and the reference product of producing are placed in to the storage of room temperature natural environment more than 3 months, add polyhydroxy ricinate finished product (experimental group) and occur without denaturalization phenomenon, the cold cream frost finished product (matched group) that does not add polyhydroxy ricinate have go mouldy, the phenomenon such as denseness reduction occurs.
Result shows that polyhydroxy ricinate has good antisepsis and sterilization and emulsibility.Although salt derivative antibacterial activity prepared by the present invention can not surmount antibiotic, its antibacterial activity can be so that it has good application prospect aspect household chemicals antibacterial anticorrosion.
Claims (8)
1. cosmetics, is characterized in that: the formula I compound that it contains effective dose; Formula I compound structure is as follows:
X is selected from alkali metal.
2. cosmetics according to claim 1, is characterized in that: X is selected from K or Na.
3. cosmetics according to claim 1, is characterized in that: formula I compound accounts for 1～10% of cosmetics total amount.
4. cosmetics according to claim 3, is characterized in that: formula I compound accounts for 1～5% of cosmetics total amount.
5. cosmetics according to claim 4, is characterized in that: formula I compound accounts for 3～5% of cosmetics total amount.
6. cosmetics according to claim 1, is characterized in that: in described cosmetics, also comprise oil phase substrate, consistency modifiers, wetting agent, emulsifying agent and water.
7. cosmetics according to claim 6, is characterized in that: described oil phase substrate is squalane; Described consistency modifiers is glyceryl monostearate and octadecanol; Described wetting agent is Polyethylene Glycol, glycerol and propylene glycol; Described emulsifying agent is Span-80 and Tween-80.
8. cosmetics according to claim 6, is characterized in that: in described cosmetics, also comprise essence, auxiliary anticorrosion agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410284294.5A CN104161678B (en) | 2014-06-23 | 2014-06-23 | A kind of cosmetics |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410284294.5A CN104161678B (en) | 2014-06-23 | 2014-06-23 | A kind of cosmetics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104161678A true CN104161678A (en) | 2014-11-26 |
| CN104161678B CN104161678B (en) | 2016-08-24 |
Family
ID=51905813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410284294.5A Active CN104161678B (en) | 2014-06-23 | 2014-06-23 | A kind of cosmetics |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104161678B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1649578A (en) * | 2002-03-04 | 2005-08-03 | 戴弗根斯公司 | Nematicidal fatty acid and fatty acid ester related compounds |
| KR20060102417A (en) * | 2005-03-23 | 2006-09-27 | 주식회사 코오롱 | Polyacetal resin composition having an excellent heat stability |
-
2014
- 2014-06-23 CN CN201410284294.5A patent/CN104161678B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1649578A (en) * | 2002-03-04 | 2005-08-03 | 戴弗根斯公司 | Nematicidal fatty acid and fatty acid ester related compounds |
| KR20060102417A (en) * | 2005-03-23 | 2006-09-27 | 주식회사 코오롱 | Polyacetal resin composition having an excellent heat stability |
Non-Patent Citations (1)
| Title |
|---|
| 胡志孟: "羟基植物油脂肪酸的抗磨规律", 《油滑与密封》, no. 4, 31 August 2001 (2001-08-31) * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104161678B (en) | 2016-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60111725T2 (en) | PERCARBONIC ACID COMPOSITIONS AND USES AGAINST MICROBIAL SPORTS | |
| AU2014362252B2 (en) | Acid-solubilized copper-ammonium complexes and copper-zinc-ammonium complexes, compositions, preparations, methods, and uses | |
| CN102459747A (en) | Antimicrobial textiles comprising peroxide | |
| CN107613767A (en) | Cooperate with anticorrosive composite | |
| CN104970043A (en) | Storage-stable, synergistic microbicidal concentrates containing an isothiazolone, an amine and an oxidizing agent | |
| EA201201463A1 (en) | STABILIZED AGROCHEMICAL COMPOSITION | |
| CN103430797A (en) | Method for preventing and controlling fungal diseases of cucumbers | |
| US20100160454A1 (en) | Antimicrobial agents, compositions and products containing the same, and methods of using the compositions and products | |
| CN108078872A (en) | Natural application of the eutectic solvent as preservative | |
| TW201218954A (en) | Microbicidal composition | |
| CN101801182A (en) | New antibacterial agent based on fatty acid esters of hydroxy carboxylic acids | |
| CN103494713A (en) | Composition with antiseptic efficacy and application thereof in cosmetics | |
| KR20150058604A (en) | Antiseptic composition for water tissue | |
| CN102293199A (en) | Disinfectant and preparation method thereof | |
| JP2012526809A (en) | Compositions and products containing alicyclic diol antimicrobial agents and methods of using the compositions and products | |
| US11279902B2 (en) | Hyperprotonation cleaning, disinfection, and sterilization compositions and methods | |
| CN104161678A (en) | Cosmetic | |
| CN102138567A (en) | Composite preparation for killing bacteria and removing algae under water environment | |
| CN104163758B (en) | The stearic salt derivative of 9,10,12-trihydroxy- | |
| CN100515200C (en) | Neodymium nitrate berberine complex pesticides sterilizing emulsion agent and preparation method thereof | |
| CN105796404A (en) | Anticorrosion composition and application to daily chemical products | |
| CN105211089A (en) | A kind of Multifunctional anti-fungus antibacterial agent | |
| CN102573859A (en) | Silver/polydiguanide complex, preparation method thereof, and antibacterial composition containing the same as an active ingredient | |
| JP5603701B2 (en) | Antibacterial composition and use thereof | |
| CN103798278B (en) | Avermectin and the composite agricultural chemicals suspension agent of azacyclotin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |